Avadel Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Jan '26 Jan 12, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Market Capitalization	2,110	1,013	-	-	-	-	Upgrade
Enterprise Value	2,056	985	-	-	-	-	Upgrade
Last Close Price	21.50	10.51	-	-	-	-	Upgrade
Forward PE	31.10	200.19	-	-	-	-	Upgrade
PS Ratio	8.37	5.99	-	-	-	-	Upgrade
PB Ratio	21.28	13.71	-	-	-	-	Upgrade
P/TBV Ratio	25.93	17.76	-	-	-	-	Upgrade
EV/Sales Ratio	8.27	5.83	-	-	-	-	Upgrade
Debt / Equity Ratio	0.38	0.53	0.41	-6.20	1.85	0.80	Upgrade
Debt / EBITDA Ratio	10.27	-	-	-	-	-	Upgrade
Debt / FCF Ratio	1.09	-	-	-	-	-	Upgrade
Asset Turnover	1.39	1.03	0.19	-	-	0.10	Upgrade
Inventory Turnover	0.63	1.00	-	-	-	-	Upgrade
Quick Ratio	2.15	2.21	3.18	1.77	8.99	17.30	Upgrade
Current Ratio	2.76	2.75	3.64	1.81	9.17	17.44	Upgrade
Return on Equity (ROE)	-0.32%	-60.44%	-481.35%	-481.49%	-64.30%	10.56%	Upgrade
Return on Assets (ROA)	-0.34%	-16.11%	-57.92%	-31.32%	-19.14%	-9.90%	Upgrade
Return on Capital (ROIC)	-0.49%	-22.41%	-73.72%	-35.73%	-20.73%	-11.64%	Upgrade
Return on Capital Employed (ROCE)	-0.70%	-36.70%	-107.80%	-123.70%	-37.80%	-12.40%	Upgrade
Earnings Yield	-0.01%	-4.82%	-	-	-	-	Upgrade
FCF Yield	1.63%	-4.63%	-	-	-	-	Upgrade
Buyback Yield / Dilution	-3.42%	-18.67%	-33.41%	-2.66%	-6.54%	-46.89%	Upgrade

Updated Nov 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q